Volume 6.00 | Jan 6

Hematopoiesis News 6.00 January 6, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
Report on Remission in Patients with MS Three Years after Stem Cell Transplant
Three years after a small number of patients with multiple sclerosis (MS) were treated with high-dose immunosuppressive therapy and then transplanted with their own hematopoietic stem cells, most of the patients sustained remission of active relapsing-remitting MS and had improvements in neurological function. [JAMA Neurol] Press Release | Full Article | Editorial
Free Poster: Quick Reference for Mouse Immune Cell Frequencies and Percentages
PUBLICATIONS (Ranked by impact factor of the journal)
Inducible RNAi In Vivo Reveals that the Transcription Factor BATF Is Required to Initiate but Not Maintain CD8+ T-Cell Effector Differentiation
Scientists demonstrate that lentivirus-transduced progenitor cells could reconstitute normal hematopoiesis and develop into naive CD8+ T cells that were indistinguishable from wild-type naive T cells. This experimental system enabled induction of efficient gene knockdown in vivo without subsequent manipulation. [Proc Natl Acad Sci USA] Abstract

Inflammatory Signaling Regulates Hematopoietic Stem and Progenitor Cell Emergence in Vertebrates
Researchers demonstrate that in both zebrafish and mouse embryos, inflammatory signaling is necessary and sufficient for hematopoietic stem and progenitor cell emergence, in the absence of infection or pathological inflammation. [Blood] Abstract

The RUNX1 +24 Enhancer and P1 Promoter Identify a Unique Subpopulation of Hematopoietic Progenitor Cells Derived from Human Pluripotent Stem Cells
Investigators used a novel genetic reporter system to prospectively identify and isolate early hematopoietic cells derived from human embryonic stem cells and human induced pluripotent cells. [Stem Cells] Abstract

Hematopoietic Stem/Progenitor Cells Directly Contribute to Arteriosclerotic Progression via Integrin Β2
Researchers hypothesized that circulating hematopoietic stem/progenitor cells may home to inflamed vessels, where they might contribute to inflammation and neointima formation. [Stem Cells] Abstract | Full Article

Contrasting Roles for C/EBPα and Notch in Irradiation-Induced Multipotent Hematopoietic Progenitor Cell Defects
Investigators demonstrate that ionizing radiation causes long-term, somatically heritable, cell-intrinsic reductions in hematopoietic stem cell and multipotent hematopoietic progenitor cell self-renewal that are mediated by C/EBPα and reversed by Notch. [Stem Cells] Abstract | Press Release

Role of the Clathrin Adaptor PICALM in Normal Hematopoiesis and Polycythemia Vera Pathophysiology
Scientists show, by employing a series of conditional Picalm knockout mice, that PICALM critically regulates transferrin uptake in erythroid cells by functioning as a cell-type-specific regulator of transferrin receptor endocytosis. [Haematologica] Abstract | Full Article

The Possible Role of Liver Kinase B1 in Hydroquinone-Induced Toxicity of Murine Fetal Liver and Bone Marrow Hematopoietic Stem Cells
Researchers hypothesize that liver kinase B1 contributes to the deregulation of fetal or bone hematopoiesis caused by the benzene metabolite hydroquinone. [Environ Toxicol] Abstract


Ibrutinib for Previously Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia with TP53 aberrations: A Phase II, Single-Arm Trial
Investigators enrolled eligible adult patients with active chronic lymphocytic leukemia with TP53 aberrations at the National Institutes of Health Clinical Center. Patients received 28-day cycles of ibrutinib 420 mg orally once daily until disease progression or the occurrence of limiting toxicities. [Lancet Oncol] Abstract | Press Release

Single and Multiple Dose MultiStem® (Multi-Potent Adult Progenitor Cell) Therapy Prophylaxis of Acute GvHD in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase I Trial
Researchers conducted a multi-center, Phase I dose escalation study evaluating safety of the allogeneic multipotent adult progenitor cell stromal product administered as an adjunct therapy to 36 patients after myeloablative allogeneic hematopoietic cell transplantation. [Biol Blood Marrow Transplant] Abstract

Prevalence and Clinical Significance of Potential Drug-Drug Interaction in Hematopoietic Stem Cell Transplantation
Investigators performed a cross-sectional study based on the evaluation of prescriptions to hematopoietic stem cell transplantation patients on the day of infusion. The potential drug-drug interactions were analyzed using the DRUG-REAX® system and classified according to the severity level, available scientific evidence, time of onset, and potential clinical impact. [Cancer Chemother Pharmacol] Abstract

Hematopoietic Stem Cell Transplantation following Unsuccessful Salvage Treatment for Relapsed Acute Lymphoblastic Leukemia in Children
The medical records of 55 children with acute lymphoblastic leukemia who underwent stem cell transplantation following the experience of re-induction failure or multiple relapses were retrospectively analyzed. [Pediatr Blood Cancer] Abstract

Got cells? Jumpstart your research with ready to use immune and hematopoietic cells.
Deciphering the Molecular Landscape in Chronic Lymphocytic Leukemia: Time Frame of Disease Evolution
Dramatic advances in next generation sequencing technologies have provided a novel opportunity to understand the molecular genetics of chronic lymphocytic leukemia through the comprehensive detection of genetic lesions. [Haematologica] Full Article

Hematopoietic Stem Cell Aging and the Prospects for Rejuvenation
Mechanistically, DNA damage and/or altered transcriptional landscapes appear to be major drivers of the hematopoietic stem cell aging state, with recent data proposing that stem cell aging phenotypes are characterized by at least some degree of reversibility. [Stem Cells Transl Med] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
ARIAD Announces Phase II Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015
ARIAD Pharmaceuticals, Inc. announced that it has concluded consultations with U.S. and European health authorities regarding the design of a randomized, dose-ranging trial to evaluate three starting doses of Iclusig® in patients with refractory, chronic-phase chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc.]
Press Release

BioLineRx Completes Dose Escalation Stage of Phase I Trial for Novel Stem Cell Mobilization Treatment
BioLineRx Ltd. announced that it has completed the dose escalation stage of a Phase I trial for its novel oncology platform, BL-8040, as a novel treatment for the mobilization of stem cells from the bone marrow to the peripheral blood circulation. [BioLineRx Ltd.] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Gordon Research Conference: Stem Cells & Cancer
February 15-20, 2015
Ventura, United States

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Fellow – Stem Cell/Translational Medicine (Rutgers New Jersey Medical School)

NEW Postdoctoral Fellow – Hematopoiesis and Stem Cell Biology (Lund University)

NEW Postdoctoral Research Scientist – Human T Cell Leukemia (Washington University School of Medicine)

NEW Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

PhD Student – Experimental Leukemia Research (University Children’s Hospital Basel)

Research Associate – Hematopoietic and Leukemic Stem Cells (Shanghai Jiao-Tong University)

Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School At Houston)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us